drugset / Trial / NCT01054768

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

NCT01054768

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of life.

Timeline

Start
2009-08
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetylcarnitine Small molecule
Subject alpha-lipoic acid Small molecule

Indications